Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Canadian Cancer Trials Group
Study ID
NCT04918186
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Durvalumab — DRUG
    1500mg IV, 60 min day 1 every 4 weeks
  • BA3011 — DRUG
    IV
  • BA3021 — DRUG
    IV
  • ENB003 — DRUG
    IV
  • Toripalimab — DRUG
    IV

Study Details

This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.

Key Dates

Start date
May 3, 2022
Status verified
Sep 2025
Primary completion
Jun 30, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Durvalumab + BA3011 (Arm Closed)
  • Experimental: Durvalumab + BA3021 (Arm Closed)
  • Experimental: ENB-003 + Toripalimab

Primary Outcome Measure

To efficiently identify based on objective response rate (ORR), by investigator assessment using RECIST 1.1, promising immunotherapy combinations for the treatment of high grade serous ovarian cancer for later validation in randomized trials [ Time Frame: 36 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Chicago Medical CenterChicagoIllinois60637
John Moroney
773-834-4732

Find similar trials in Chicago, IL

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
The University of Chicago Medical Center· Chicago, IL

Related Studies